Home>Topics>Stocks>Nektar Therapeutics

Nektar Therapeutics NKTR

  1. All
  2. Commentary
  3. Headlines
    1. Ad Comm supports approval of Moventig for OIC

      Headlines

      Fri, 26 Sep 2014

      positive opinion recommending approval of Nektar Therapeutics ' (NASDAQ: NKTR ) Moventig ( naloxegol ) for the treatment ..... gastrointestinal tract. The drug candidate is based on Nektar Therapeutics ' ( NKTR ) oral small molecule polymer conjugate technology

    2. Relistor in OIC PDUFA approaches

      Headlines

      Tue, 23 Sep 2014

      treatment of opioid-induced constipation (OIC). Salix ( SLXP +5% ) successfully appealed the FDA's CRL for the indication in July. ( PGNX +0.6% )( NKTR +1.8% )( AZN -4% )( CBST +0.6% )( SGYP +3.1% ) Post your comment!

    3. CORRECTED-FDA approves AstraZeneca, Nektar constipation drug

      Headlines

      Tue, 16 Sep 2014

      Sept 16 (Reuters) - The U.S. Food and Drug Administration approved an oral therapy to treat opioid-induced constipation developed by Nektar Therapeutics and AstraZeneca Plc .

    4. FDA clears OIC drug

      Headlines

      Tue, 16 Sep 2014

      The FDA approves Nektar Therapeutics ' ( NKTR -0.1% ) Movantik ( naloxegol ) for the treatment of patients with opioid-induced constipation who take opioids for the management

    5. Vectura Group Following A Familiar Path

      Headlines

      Sat, 13 Sep 2014

      By Stephen Simpson, CFA : Investors who like Nektar Therapeutics (NASDAQ: NKTR ) or Alkermes (NASDAQ: ALKS ) may want to take a look at Britain's Vectura Group plc (OTC: VEGPF ) (VEC.L). Although

    6. Nektar 181 Could Dominate A $13B Chronic Pain Market

      Headlines

      Tue, 26 Aug 2014

      By Scrying Biotech : Chronic pain suppression in the U.S. is a $13B market annually whose landscape is constantly changing based upon the unintended consequences of drug addiction. The most popular of these opiates is Purdue's OxyContin, ranked 18th in total U.S. sales last year at $2.46B. Sales of

    7. Nektar Therapeutics Has More To Give

      Headlines

      Thu, 21 Aug 2014

      develop broad pipelines have fared a little better. Nektar Therapeutics (NASDAQ: NKTR ) belongs on that list, as the company continues ..... Nektar's PEGylated naloxol (also known as NKTR -118) has less than a month to go before it should

    8. 2nd Half Of 2014 Biotechnology Catalysts - Part 4

      Headlines

      Sun, 17 Aug 2014

      By Alexander Maxwell : Having previously updated the investment community in part 3 of my Biotechnology Catalysts series, the purpose of this article is to help give investors an idea of the upcoming biotechnology catalysts through the end of September. It can be hard for investors to be able to ...

    9. Nektar Therapeutics pain drug for knee arthritis fails study

      Headlines

      Thu, 26 Sep 2013

      (Reuters) - Nektar Therapeutics said its experimental drug to treat chronic pain in patients with arthritis of the knee failed to meet its main goal in a mid-stage clinical trial.

    10. Dropping Coverage of Nektar

      Commentary

      Mon, 27 Jul 2009

      We are dropping coverage of Nektar Therapeutics NKTR to focus our resources elsewhere.

    « Prev123Next »
    Content Partners